Representative Marjorie Taylor Greene, a Republican from Georgia, has recently made significant stock purchases, including shares in Novo Nordisk A/S (NYSE:NVO). According to a filing made public on October 20, 2025, Greene acquired between $1,001 and $15,000 worth of shares in the pharmaceutical company on October 15, 2025.
In addition to her investment in Novo Nordisk, Greene has expanded her portfolio with several other notable trades on the same day. She purchased shares of Amazon.com (NASDAQ:AMZN), Adobe (NASDAQ:ADBE), Exelon (NASDAQ:EXC), iShares Bitcoin Trust ETF (NASDAQ:IBIT), and Tesla (NASDAQ:TSLA), each within the same financial range of $1,001 to $15,000.
Novo Nordisk’s Stock Performance and Financial Overview
As of the last trading session, Novo Nordisk shares opened at $53.37. The company’s stock has experienced fluctuations over the past year, with a 52-week low of $45.05 and a high of $116.43. The market capitalization stands at approximately $238.29 billion, accompanied by a price-to-earnings (P/E) ratio of 14.66 and a P/E/G ratio of 2.49.
In its latest earnings report released on August 6, 2025, Novo Nordisk reported earnings per share (EPS) of $0.97, surpassing analyst predictions of $0.93. The company generated revenue of $11.69 billion for the quarter, contributing to a net margin of 35.60% and a return on equity of 78.64%.
Most recently, Novo Nordisk declared a semi-annual dividend of $0.4119, which was paid out on August 26, 2025, to investors on record as of August 18, 2025. This dividend reflects a yield of 240.0%, with a payout ratio of 22.53%.
Analyst Ratings and Institutional Investments
Recent evaluations of Novo Nordisk’s stock by various analysts have led to a range of ratings. Notably, Sanford C. Bernstein upgraded the stock from “market perform” to “outperform” on September 9, 2025. Conversely, Morgan Stanley adjusted its rating from “overweight” to “underweight,” lowering its price target from $59.00 to $47.00 on September 29, 2025.
Overall, two analysts have rated Novo Nordisk as a Strong Buy, while seven have assigned it a Buy rating. The stock has received ten Hold ratings and one Sell rating. According to data from MarketBeat, the consensus price target stands at $76.00, indicating a “Moderate Buy” average rating.
Institutional investors have shown growing interest in Novo Nordisk, with several firms adjusting their holdings. For instance, Jennison Associates LLC increased its stake by 0.3%, while Loomis Sayles & Co. L P expanded its holdings by 1.5%. Other notable investors, such as Kingstone Capital Partners Texas LLC, reported a massive increase in its shares by over 301,000%.
About Marjorie Taylor Greene and Novo Nordisk A/S
Marjorie Taylor Greene has been serving in the U.S. House of Representatives since assuming office on January 3, 2021. She represents Georgia’s 14th Congressional District and is currently running for re-election, with her term set to conclude on January 3, 2027.
Novo Nordisk A/S, headquartered in Denmark, specializes in the research, development, and manufacturing of pharmaceutical products, particularly in diabetes and obesity care, as well as rare diseases. The company operates globally, serving markets across Europe, the Middle East, Africa, Asia, and North America.
As the stock market continues to fluctuate, the actions of influential political figures like Greene may attract scrutiny and speculation among investors and analysts alike.